A Phase 3 interventional study of 20-valent pneumococcal conjugate vaccine and 13-valent pneumococcal conjugate vaccine in Pneumococcal Disease, sponsored by Pfizer. Completed at 97 sites in 11 countries. Open to participants aged 42 Days to 98 Days, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-06-13.
Sponsored by Pfizer · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing Pneumococcal 20-Valent Conjugate Vaccine in Pneumococcal Infections — 2 open to participants now, 3 under way, 1 of them phase 3. Pneumococcal 20-Valent Conjugate Vaccine · Pneumococcal Infections.
Among the 19 studies testing Pneumococcal 20-Valent Conjugate Vaccine in Pneumococcal Infections, this one is the 4th largest by enrollment, is one of 5 that started in 2020, is one of 14 in phase 3, and was the 4th registered.
299 studies on the registry are indexed under Pneumococcal Infections; 26 are open to participants now.
Browse Pneumococcal Infections studies →2 of the 19 studies testing Pneumococcal 20-Valent Conjugate Vaccine in Pneumococcal Infections are open now, in 2 countries. Recruiting first, the newest first:
Pfizer · Sites in China
Ages 42 days–98 days · Healthy volunteers
Merck Sharp & Dohme LLC · Sites in United States
Ages 2 mo–15 mo · Healthy volunteers
By country, each count listing its studies:
Pneumococcal 20-Valent Conjugate Vaccine: first FDA approval 2021 (Prevnar 20). What it is approved for, and how studies give it, is on its page →
Of the 20 Pneumococcal Infections studies recruiting now, 4 (20%) set no upper age limit and 14 (70%) stop at 75 or younger; 14 take children under 18; 16 take healthy volunteers.
This study: 42 Days to 98 Days · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2018; this study’s year is marked. 5 started in 2020.
This study's enrollment of 1,511 is above the median of 379 across 254 interventional studies indexed under Pneumococcal Infections.
Median enrollment 668 across the 19 interventional studies. Of the 15 that completed or were terminated, 13 (87%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 19 have an industry lead sponsor. The 4 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 148 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
75 studies in Pneumococcal Infections by Pfizer: 4 open now, 8 under way, 5 of them phase 3. Of 67 finished, 45 (67%) have results posted.
Among the 75 studies in Pneumococcal Infections by Pfizer, this one is the 13th largest by enrollment of the 57 interventional ones that give a count, is one of 6 that started in 2020, is one of 33 in phase 3, and was the 49th registered.
Pfizer’s Pneumococcal Infections studies by the year they started, since 2001.
1 of the studies testing Pneumococcal 20-Valent Conjugate Vaccine in Pneumococcal Infections that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07023081PfizerA Study to Understand the Safety of the 20vPnC Vaccine in Healthy Chinese Adults, Children, and Infant | 2027-06-10 |
Add it to your calendar (.ics) → With an account.
Among the 19 studies testing Pneumococcal 20-Valent Conjugate Vaccine in Pneumococcal Infections, from their registry updates:
Among Pfizer’s 75 in Pneumococcal Infections:
This tab as a report to print or save as PDF → With an account.
This study is designed to evaluate the safety and tolerability of 20vPnC in healthy infants.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Pneumococcal conjugate vaccine
Biological: 20-valent pneumococcal conjugate vaccine
Pneumococcal conjugate vaccine
Biological: 13-valent pneumococcal conjugate vaccine
Pneumococcal conjugate vaccine
Pneumococcal conjugate vaccine
Percentage of Participants With Local Reactions Within 7 Days After Dose 1
Local reactions included pain at injection site, redness and swelling, recorded by parent's/legal guardians of participants in an electronic diary (e-diary). Redness and swelling were measured and recorded in measuring device (caliper) units. 1 measuring device unit =0.5 centimeter (cm). Redness and swelling were graded as mild: greater than (\>) 0.0 to 2.0 cm; moderate: \>2.0 to 7.0 cm; and severe: \>7.0 cm. Pain at injection site was graded as mild: hurt if gently touched; moderate: hurt if gently touched with crying; severe: limited limb movement.
Time frame: Within 7 Days after Dose 1
Percentage of Participants With Local Reactions Within 7 Days After Dose 2
Local reactions included pain at injection site, redness and swelling, recorded by parent's/legal guardians of participants in an e-diary. Redness and swelling were measured and recorded in measuring device (caliper) units. 1 measuring device unit =0.5 cm. Redness and swelling were graded as mild: \>0.0 to 2.0 cm; moderate: \>2.0 to 7.0 cm; and severe: \>7.0 cm. Pain at injection site was graded as mild: hurt if gently touched; moderate: hurt if gently touched with crying; severe: limited limb movement.
Time frame: Within 7 Days after Dose 2
Percentage of Participants With Local Reactions Within 7 Days After Dose 3
Local reactions included pain at injection site, redness and swelling, recorded by parent's/legal guardians of participants in an e-diary. Redness and swelling were measured and recorded in measuring device (caliper) units. 1 measuring device unit =0.5 cm. Redness and swelling were graded as mild: \>0.0 to 2.0 cm; moderate: \>2.0 to 7.0 cm; and severe: \>7.0 cm. Pain at injection site was graded as mild: hurt if gently touched; moderate: hurt if gently touched with crying; severe: limited limb movement.
Time frame: Within 7 Days after Dose 3
Percentage of Participants With Local Reactions Within 7 Days After Dose 4
Local reactions included pain at injection site, redness and swelling, recorded by parent's/legal guardians of participants in an e-diary. Redness and swelling were measured and recorded in measuring device (caliper) units. 1 measuring device unit =0.5 cm. Redness and swelling were graded as mild: \>0.0 to 2.0 cm; moderate: \>2.0 to 7.0 cm; and severe: \>7.0 cm. Pain at injection site was graded as mild: hurt if gently touched; moderate: hurt if gently touched with crying; severe: limited limb movement.
Time frame: Within 7 Days after Dose 4
Percentage of Participants With Systemic Events Within 7 Days After Dose 1
Systemic events included fever, decreased appetite, drowsiness, and irritability. Fever was defined as temperature greater than or equal to (\>=) 38.0 degrees Celsius (C) and categorized as \>=38.0 to 38.4 degrees C, \>38.4 to 38.9 degrees C, \>38.9 to 40.0 degrees C and \>40.0 degrees C. Decreased appetite was graded as mild (decreased interest in eating), moderate (decreased oral intake) and severe (refusal to feed). Drowsiness was graded as mild (increased or prolonged sleeping bouts), moderate (slightly subdued, interfered with daily activity) and severe (disabling, not interested in usual daily activity). Irritability was graded as mild (easily consolable), moderate (required increased attention) and severe (inconsolable, crying could not be comforted).
Time frame: Within 7 Days after Dose 1
Percentage of Participants With Systemic Events Within 7 Days After Dose 2
Systemic events included fever, decreased appetite, drowsiness, and irritability. Fever was defined as temperature \>=38.0 degrees C and categorized as \>=38.0 to 38.4 degrees C, \>38.4 to 38.9 degrees C, \>38.9 to 40.0 degrees C and \>40.0 degrees C. Decreased appetite was graded as mild (decreased interest in eating), moderate (decreased oral intake) and severe (refusal to feed). Drowsiness was graded as mild (increased or prolonged sleeping bouts), moderate (slightly subdued, interfered with daily activity) and severe (disabling, not interested in usual daily activity). Irritability was graded as mild (easily consolable), moderate (required increased attention) and severe (inconsolable, crying could not be comforted).
Time frame: Within 7 Days after Dose 2
Percentage of Participants With Systemic Events Within 7 Days After Dose 3
Systemic events included fever, decreased appetite, drowsiness, and irritability. Fever was defined as temperature \>=38.0 degrees C and categorized as \>=38.0 to 38.4 degrees C, \>38.4 to 38.9 degrees C, \>38.9 to 40.0 degrees C and \>40.0 degrees C. Decreased appetite was graded as mild (decreased interest in eating), moderate (decreased oral intake) and severe (refusal to feed). Drowsiness was graded as mild (increased or prolonged sleeping bouts), moderate (slightly subdued, interfered with daily activity) and severe (disabling, not interested in usual daily activity). Irritability was graded as mild (easily consolable), moderate (required increased attention) and severe (inconsolable, crying could not be comforted).
Time frame: Within 7 Days after Dose 3
Percentage of Participants With Systemic Events Within 7 Days After Dose 4
Systemic events included fever, decreased appetite, drowsiness, and irritability. Fever was defined as temperature \>=38.0 degrees C and categorized as \>=38.0 to 38.4 degrees C, \>38.4 to 38.9 degrees C, \>38.9 to 40.0 degrees C and \>40.0 degrees C. Decreased appetite was graded as mild (decreased interest in eating), moderate (decreased oral intake) and severe (refusal to feed). Drowsiness was graded as mild (increased or prolonged sleeping bouts), moderate (slightly subdued, interfered with daily activity) and severe (disabling, not interested in usual daily activity). Irritability was graded as mild (easily consolable), moderate (required increased attention) and severe (inconsolable, crying could not be comforted).
Time frame: Within 7 Days after Dose 4
Percentage of Participants With Adverse Events (AEs) From Dose 1 to 1 Month After Dose 3
An AE was any untoward medical occurrence in a participant, temporally associated with the use of study vaccine, whether or not considered related to the study vaccine. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.
Time frame: From Dose 1 to 1 Month after Dose 3
Percentage of Participants With AEs From Dose 4 to 1 Month After Dose 4
An AE was any untoward medical occurrence in a participant, temporally associated with the use of study vaccine, whether or not considered related to the study vaccine. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.
Time frame: From Dose 4 to 1 Month after Dose 4
Percentage of Participants With Serious Adverse Events (SAEs) From Dose 1 to 6 Months After Dose 4
A SAE was any untoward medical occurrence that, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent or significant disability/incapacity; congenital anomaly/birth defect and other important medical events.
Time frame: From Dose 1 to 6 Months after Dose 4
Percentage of Participants With Newly Diagnosed Chronic Medical Conditions (NDCMCs) From Dose 1 to 6 Months After Dose 4
An NDCMC was defined as a significant disease or medical condition, not previously identified, that is expected to be persistent or was otherwise long-lasting in its effects.
Time frame: From Dose 1 to 6 Months after Dose 4
| Milestone | 20vPnC | 13vPnC |
|---|---|---|
| Started | 1006 | 505 |
| Dose 1 | 1000 | 504 |
| Dose 2 | 972 | 492 |
| Dose 3 | 964 | 483 |
| Dose 4 | 923 | 462 |
| Completed | 910 | 451 |
| Not completed | 96 | 54 |
| Withdrew: Adverse event | 2 | 0 |
| Withdrew: Physician decision | 2 | 1 |
| Withdrew: Protocol violation | 11 | 6 |
| Withdrew: No longer met eligibility criteria | 14 | 11 |
| Withdrew: Withdrawal by parent/guardian | 36 | 15 |
| Withdrew: Lost to follow-up | 31 | 21 |
Local reactions included pain at injection site, redness and swelling, recorded by parent's/legal guardians of participants in an electronic diary (e-diary). Redness and swelling were measured and recorded in measuring device (caliper) units. 1 measuring device unit =0.5 centimeter (cm). Redness and swelling were graded as mild: greater than (\>) 0.0 to 2.0 cm; moderate: \>2.0 to 7.0 cm; and severe: \>7.0 cm. Pain at injection site was graded as mild: hurt if gently touched; moderate: hurt if gently touched with crying; severe: limited limb movement.
| Percentage of participants | 20vPnC | 13vPnC |
|---|---|---|
| Redness: Mild | 18.0 ± 15.7 | 16.5 ± 13.3 |
| Redness: Moderate | 3.7 ± 2.6 | 3.0 ± 1.7 |
| Redness: Severe | 0 ± 0.0 | 0 ± 0.0 |
| Swelling: Mild | 13.8 ± 11.7 | 11.2 ± 8.6 |
| Swelling: Moderate | 6.1 ± 4.7 | 5.4 ± 3.6 |
| Swelling: Severe | 0 ± 0.0 | 0 ± 0.0 |
| Pain at injection site: Mild | 24.8 ± 22.1 | 25.3 ± 21.5 |
| Pain at injection site: Moderate | 15.5 ± 13.3 | 16.7 ± 13.5 |
| Pain at injection site: Severe | 0.2 ± 0.0 | 0 ± 0.0 |
Local reactions included pain at injection site, redness and swelling, recorded by parent's/legal guardians of participants in an e-diary. Redness and swelling were measured and recorded in measuring device (caliper) units. 1 measuring device unit =0.5 cm. Redness and swelling were graded as mild: \>0.0 to 2.0 cm; moderate: \>2.0 to 7.0 cm; and severe: \>7.0 cm. Pain at injection site was graded as mild: hurt if gently touched; moderate: hurt if gently touched with crying; severe: limited limb movement.
| Percentage of participants | 20vPnC | 13vPnC |
|---|---|---|
| Redness: Mild | 20.4 ± 17.9 | 19.4 ± 16.0 |
| Redness: Moderate | 3.2 ± 2.1 | 3.9 ± 2.4 |
| Redness: Severe | 0 ± 0.0 | 0 ± 0.0 |
| Swelling: Mild | 13.4 ± 11.3 | 13.4 ± 10.5 |
| Swelling: Moderate | 4.4 ± 3.2 | 5.6 ± 3.7 |
| Swelling: Severe | 0 ± 0.0 | 0 ± 0.0 |
| Pain at the injection site: Mild | 20.8 ± 18.3 | 20.2 ± 16.7 |
| Pain at the injection site: Moderate | 10.7 ± 8.8 | 11.8 ± 9.0 |
| Pain at the injection site: Severe | 0.7 ± 0.3 | 0.8 ± 0.2 |
Local reactions included pain at injection site, redness and swelling, recorded by parent's/legal guardians of participants in an e-diary. Redness and swelling were measured and recorded in measuring device (caliper) units. 1 measuring device unit =0.5 cm. Redness and swelling were graded as mild: \>0.0 to 2.0 cm; moderate: \>2.0 to 7.0 cm; and severe: \>7.0 cm. Pain at injection site was graded as mild: hurt if gently touched; moderate: hurt if gently touched with crying; severe: limited limb movement.
| Percentage of participants | 20vPnC | 13vPnC |
|---|---|---|
| Redness: Mild | 19.4 ± 16.9 | 17.0 ± 13.7 |
| Redness: Moderate | 3.8 ± 2.7 | 3.1 ± 1.8 |
| Redness: Severe | 0 ± 0.0 | 0.2 ± 0.0 |
| Swelling: Mild | 12.2 ± 10.2 | 13.0 ± 10.1 |
| Swelling: Moderate | 4.1 ± 3.0 | 3.1 ± 1.8 |
| Swelling: Severe | 0 ± 0.0 | 0.2 ± 0.0 |
| Pain at the injection site: Mild | 16.3 ± 14.0 | 16.6 ± 13.3 |
| Pain at the injection site: Moderate | 8.3 ± 6.6 | 10.3 ± 7.7 |
| Pain at the injection site: Severe | 0.1 ± 0.0 | 0 ± 0.0 |
Local reactions included pain at injection site, redness and swelling, recorded by parent's/legal guardians of participants in an e-diary. Redness and swelling were measured and recorded in measuring device (caliper) units. 1 measuring device unit =0.5 cm. Redness and swelling were graded as mild: \>0.0 to 2.0 cm; moderate: \>2.0 to 7.0 cm; and severe: \>7.0 cm. Pain at injection site was graded as mild: hurt if gently touched; moderate: hurt if gently touched with crying; severe: limited limb movement.
| Percentage of participants | 20vPnC | 13vPnC |
|---|---|---|
| Redness: Mild | 15.1 ± 12.8 | 19.4 ± 15.8 |
| Redness: Moderate | 5.9 ± 4.5 | 2.4 ± 1.2 |
| Redness: Severe | 0.1 ± 0.0 | 0 ± 0.0 |
| Swelling: Mild | 10.1 ± 8.2 | 11.5 ± 8.7 |
| Swelling: Moderate | 4.7 ± 3.4 | 2.9 ± 1.5 |
| Swelling: Severe | 0 ± 0.0 | 0 ± 0.0 |
| Pain at the injection site: Mild | 19.8 ± 17.3 | 21.8 ± 18.1 |
| Pain at the injection site: Moderate | 10.2 ± 8.3 | 10.1 ± 7.5 |
| Pain at the injection site: Severe | 0.8 ± 0.3 | 0 ± 0.0 |
Systemic events included fever, decreased appetite, drowsiness, and irritability. Fever was defined as temperature greater than or equal to (\>=) 38.0 degrees Celsius (C) and categorized as \>=38.0 to 38.4 degrees C, \>38.4 to 38.9 degrees C, \>38.9 to 40.0 degrees C and \>40.0 degrees C. Decreased appetite was graded as mild (decreased interest in eating), moderate (decreased oral intake) and severe (refusal to feed). Drowsiness was graded as mild (increased or prolonged sleeping bouts), moderate (slightly subdued, interfered with daily activity) and severe (disabling, not interested in usual daily activity). Irritability was graded as mild (easily consolable), moderate (required increased attention) and severe (inconsolable, crying could not be comforted).
| Percentage of participants | 20vPnC | 13vPnC |
|---|---|---|
| Fever: >=38.0 degrees C to 38.4 degrees C | 6.3 (4.8 to 7.9) | 7.8 (5.6 to 10.6) |
| Fever: >38.4 degrees C to 38.9 degrees C | 2.3 (1.5 to 3.5) | 1.8 (0.8 to 3.4) |
| Fever: >38.9 degrees C to 40.0 degrees C | 0.7 (0.3 to 1.4) | 0.2 (0.0 to 1.1) |
| Fever: >40.0 degrees C | 0 (0.0 to 0.4) | 0 (0.0 to 0.7) |
| Decreased appetite: Mild | 14.2 (12.1 to 16.5) | 14.7 (11.7 to 18.1) |
| Decreased appetite: Moderate | 10.3 (8.5 to 12.3) | 8.6 (6.3 to 11.5) |
| Decreased appetite: Severe | 0.5 (0.2 to 1.2) | 0.4 (0.0 to 1.4) |
| Drowsiness: Mild | 48.5 (45.3 to 51.6) | 47.4 (42.9 to 51.9) |
| Drowsiness: Moderate | 15.8 (13.6 to 18.2) | 14.5 (11.5 to 17.9) |
| Drowsiness: Severe | 0.5 (0.2 to 1.2) | 0.4 (0.0 to 1.4) |
| Irritability: Mild | 22.7 (20.1 to 25.4) | 22.9 (19.3 to 26.8) |
| Irritability: Moderate | 41.2 (38.1 to 44.4) | 41.4 (37.0 to 45.8) |
| Irritability: Severe | 4.3 (3.2 to 5.8) | 4.2 (2.6 to 6.4) |
Systemic events included fever, decreased appetite, drowsiness, and irritability. Fever was defined as temperature \>=38.0 degrees C and categorized as \>=38.0 to 38.4 degrees C, \>38.4 to 38.9 degrees C, \>38.9 to 40.0 degrees C and \>40.0 degrees C. Decreased appetite was graded as mild (decreased interest in eating), moderate (decreased oral intake) and severe (refusal to feed). Drowsiness was graded as mild (increased or prolonged sleeping bouts), moderate (slightly subdued, interfered with daily activity) and severe (disabling, not interested in usual daily activity). Irritability was graded as mild (easily consolable), moderate (required increased attention) and severe (inconsolable, crying could not be comforted).
| Percentage of participants | 20vPnC | 13vPnC |
|---|---|---|
| Fever: >=38.0 degrees C to 38.4 degrees C | 10.6 (8.7 to 12.7) | 8.5 (6.1 to 11.3) |
| Fever: >38.4 degrees C to 38.9 degrees C | 3.6 (2.5 to 5.0) | 2.7 (1.4 to 4.5) |
| Fever: >38.9 degrees C to 40.0 degrees C | 1.4 (0.7 to 2.3) | 0.2 (0.0 to 1.1) |
| Fever: >40.0 degrees C | 0 (0.0 to 0.4) | 0 (0.0 to 0.8) |
| Decreased appetite: Mild | 13.4 (11.3 to 15.8) | 12.0 (9.2 to 15.2) |
| Decreased appetite: Moderate | 9.6 (7.8 to 11.6) | 8.2 (6.0 to 11.1) |
| Decreased appetite: Severe | 0.7 (0.3 to 1.5) | 0.4 (0.0 to 1.5) |
| Drowsiness: Mild | 35.3 (32.3 to 38.4) | 35.3 (31.0 to 39.7) |
| Drowsiness: Moderate | 13.4 (11.3 to 15.8) | 13.8 (10.9 to 17.2) |
| Drowsiness: Severe | 0.4 (0.1 to 1.1) | 1.2 (0.5 to 2.7) |
| Irritability: Mild | 23.2 (20.6 to 26.0) | 19.8 (16.3 to 23.6) |
| Irritability: Moderate | 37.3 (34.2 to 40.4) | 42.7 (38.2 to 47.2) |
| Irritability: Severe | 4.2 (3.0 to 5.7) | 5.2 (3.4 to 7.5) |
Systemic events included fever, decreased appetite, drowsiness, and irritability. Fever was defined as temperature \>=38.0 degrees C and categorized as \>=38.0 to 38.4 degrees C, \>38.4 to 38.9 degrees C, \>38.9 to 40.0 degrees C and \>40.0 degrees C. Decreased appetite was graded as mild (decreased interest in eating), moderate (decreased oral intake) and severe (refusal to feed). Drowsiness was graded as mild (increased or prolonged sleeping bouts), moderate (slightly subdued, interfered with daily activity) and severe (disabling, not interested in usual daily activity). Irritability was graded as mild (easily consolable), moderate (required increased attention) and severe (inconsolable, crying could not be comforted).
| Percentage of participants | 20vPnC | 13vPnC |
|---|---|---|
| Fever: >=38.0 degrees C to 38.4 degrees C | 7.4 (5.9 to 9.3) | 8.2 (5.9 to 11.0) |
| Fever: >38.4 degrees C to 38.9 degrees C | 2.9 (1.9 to 4.2) | 0.6 (0.1 to 1.8) |
| Fever: >38.9 degrees C to 40.0 degrees C | 1.3 (0.7 to 2.2) | 1.0 (0.3 to 2.4) |
| Fever: >40.0 degrees C | 0 (0.0 to 0.4) | 0 (0.0 to 0.8) |
| Decreased appetite: Mild | 15.0 (12.8 to 17.4) | 10.5 (7.9 to 13.6) |
| Decreased appetite: Moderate | 8.2 (6.5 to 10.1) | 6.3 (4.3 to 8.9) |
| Decreased appetite: Severe | 0.4 (0.1 to 1.1) | 0.4 (0.1 to 1.5) |
| Drowsiness: Mild | 26.6 (23.8 to 29.5) | 27.3 (23.3 to 31.5) |
| Drowsiness: Moderate | 8.5 (6.8 to 10.5) | 9.0 (6.6 to 12.0) |
| Drowsiness: Severe | 0.2 (0.0 to 0.8) | 0 (0.0 to 0.8) |
| Irritability: Mild | 22.3 (19.7 to 25.1) | 22.2 (18.6 to 26.2) |
| Irritability: Moderate | 30.1 (27.2 to 33.2) | 29.8 (25.7 to 34.1) |
| Irritability: Severe | 2.3 (1.5 to 3.5) | 2.7 (1.5 to 4.6) |
Systemic events included fever, decreased appetite, drowsiness, and irritability. Fever was defined as temperature \>=38.0 degrees C and categorized as \>=38.0 to 38.4 degrees C, \>38.4 to 38.9 degrees C, \>38.9 to 40.0 degrees C and \>40.0 degrees C. Decreased appetite was graded as mild (decreased interest in eating), moderate (decreased oral intake) and severe (refusal to feed). Drowsiness was graded as mild (increased or prolonged sleeping bouts), moderate (slightly subdued, interfered with daily activity) and severe (disabling, not interested in usual daily activity). Irritability was graded as mild (easily consolable), moderate (required increased attention) and severe (inconsolable, crying could not be comforted).
| Percentage of participants | 20vPnC | 13vPnC |
|---|---|---|
| Fever: >=38.0 degrees C to 38.4 degrees C | 9.8 (7.9 to 11.9) | 9.5 (6.9 to 12.5) |
| Fever: >38.4 degrees C to 38.9 degrees C | 4.5 (3.2 to 6.1) | 4.2 (2.5 to 6.5) |
| Fever: >38.9 degrees C to 40.0 degrees C | 3.7 (2.6 to 5.2) | 3.1 (1.7 to 5.1) |
| Fever: >40.0 degrees C | 0.1 (0.0 to 0.6) | 0.2 (0.0 to 1.2) |
| Decreased appetite: Mild | 16.1 (13.8 to 18.7) | 12.3 (9.5 to 15.7) |
| Decreased appetite: Moderate | 10.5 (8.6 to 12.7) | 11.7 (8.9 to 15.0) |
| Decreased appetite: Severe | 1.7 (0.9 to 2.8) | 1.8 (0.8 to 3.4) |
| Drowsiness: Mild | 24.2 (21.4 to 27.2) | 25.1 (21.2 to 29.4) |
| Drowsiness: Moderate | 12.2 (10.1 to 14.6) | 10.6 (7.9 to 13.8) |
| Drowsiness: Severe | 0.7 (0.2 to 1.5) | 0.2 (0.0 to 1.2) |
| Irritability: Mild | 21.4 (18.8 to 24.3) | 22.0 (18.3 to 26.1) |
| Irritability: Moderate | 31.4 (28.4 to 34.5) | 29.7 (25.6 to 34.2) |
| Irritability: Severe | 2.5 (1.6 to 3.7) | 3.3 (1.9 to 5.4) |
An AE was any untoward medical occurrence in a participant, temporally associated with the use of study vaccine, whether or not considered related to the study vaccine. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.
| Percentage of participants | 20vPnC | 13vPnC |
|---|---|---|
| Percentage of Participants With Adverse Events (AEs) From Dose 1 to 1 Month After Dose 3 | 29.6 ± 26.8 | 27.6 ± 23.8 |
An AE was any untoward medical occurrence in a participant, temporally associated with the use of study vaccine, whether or not considered related to the study vaccine. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.
| Percentage of participants | 20vPnC | 13vPnC |
|---|---|---|
| Percentage of Participants With AEs From Dose 4 to 1 Month After Dose 4 | 15.1 ± 12.8 | 15.8 ± 12.6 |
A SAE was any untoward medical occurrence that, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent or significant disability/incapacity; congenital anomaly/birth defect and other important medical events.
| Percentage of participants | 20vPnC | 13vPnC |
|---|---|---|
| Percentage of Participants With Serious Adverse Events (SAEs) From Dose 1 to 6 Months After Dose 4 | 4.4 ± 3.2 | 5.6 ± 3.7 |
An NDCMC was defined as a significant disease or medical condition, not previously identified, that is expected to be persistent or was otherwise long-lasting in its effects.
| Percentage of participants | 20vPnC | 13vPnC |
|---|---|---|
| Percentage of Participants With Newly Diagnosed Chronic Medical Conditions (NDCMCs) From Dose 1 to 6 Months After Dose 4 | 2.8 ± 1.9 | 2.8 ± 1.5 |
Collected over Local reactions and systemic events recorded using systematic assessment: within 7 days after Dose 1, 2, 3, 4; SAEs and all-cause mortality recorded using non-systematic assessment: From Dose 1 up to 6 months after Dose 4; other AEs recorded using non-systematic assessment: from Dose 1 up to 1 month after Dose 3 and from Dose 4 up to 1 month after Dose 4. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 20vPnC | 0/1,000 (0%) | 44/1,000 (4.4%) | 960/1,000 (96%) |
| 13vPnC | 0/503 (0%) | 28/503 (5.6%) | 481/503 (95.6%) |
| Event | 20vPnC | 13vPnC |
|---|---|---|
| BronchiolitisInfections and infestations | 5/1000 | 5/503 |
| PyrexiaGeneral disorders | 1/1000 | 3/503 |
| GastroenteritisInfections and infestations | 3/1000 | 2/503 |
| Otitis media acuteInfections and infestations | 1/1000 | 2/503 |
| Urinary tract infectionInfections and infestations | 1/1000 | 2/503 |
| Adenovirus infectionInfections and infestations | 2/1000 | 0/503 |
| PneumoniaInfections and infestations | 2/1000 | 0/503 |
| Respiratory syncytial virus infectionInfections and infestations | 2/1000 | 0/503 |
| AnaemiaBlood and lymphatic system disorders | 0/1000 | 1/503 |
| Allergic colitisGastrointestinal disorders | 0/1000 | 1/503 |
| Event | 20vPnC | 13vPnC |
|---|---|---|
| Irritability (IRRITABILITY)Psychiatric disorders | 883/1000 | 432/503 |
| Hypersomnia (INCREASED SLEEP)Nervous system disorders | 809/1000 | 389/503 |
| Injection site pain (PAIN)General disorders | 609/1000 | 309/503 |
| Decreased appetite (DECREASED APPETITE)Metabolism and nutrition disorders | 549/1000 | 249/503 |
| Injection site erythema (REDNESS)General disorders | 455/1000 | 224/503 |
| Injection site swelling (SWELLING)General disorders | 372/1000 | 176/503 |
| Pyrexia (FEVER)General disorders | 336/1000 | 159/503 |
| Upper respiratory tract infectionInfections and infestations | 59/1000 | 28/503 |
Safety population included all participants who received at least 1 dose of the investigational product with safety follow up after any dose. Participant who received any incorrect study vaccination during the study was excluded.
| Age, Continuous(Days) | 20vPnC | 13vPnC | Total |
|---|---|---|---|
| Mean | 64.6 ± 8.51 | 65.0 ± 8.95 | 64.8 ± 8.66 |
| Sex: Female, Male(Participants) | 20vPnC | 13vPnC | Total |
|---|---|---|---|
| Female | 483 | 259 | 742 |
| Male | 517 | 244 | 761 |
| Ethnicity (NIH/OMB)(Participants) | 20vPnC | 13vPnC | Total |
|---|---|---|---|
| Hispanic or Latino | 367 | 193 | 560 |
| Not Hispanic or Latino | 621 | 303 | 924 |
| Unknown or Not Reported | 12 | 7 | 19 |
| Race (NIH/OMB)(Participants) | 20vPnC | 13vPnC | Total |
|---|---|---|---|
| American Indian or Alaska Native | 4 | 1 | 5 |
| Asian | 21 | 10 | 31 |
| Native Hawaiian or Other Pacific Islander | 2 | 2 | 4 |
| Black or African American | 55 | 15 | 70 |
| White | 868 | 445 | 1313 |
| More than one race | 35 | 21 | 56 |
| Unknown or Not Reported | 15 | 9 | 24 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from May 2020 to primary completion in Aug 2022, 27 months.
Results were first posted in Jun 2023, 9 months after primary completion.
Of 81 industry-sponsored phase 3 interventional studies under Pneumococcal Infections, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 23. This study's 27 months is above that.
Counting every sponsor, half of 82 studies reached it within 13 months; a quarter within 9 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pneumococcal 20-Valent Conjugate Vaccine